MCID: ACT020
MIFTS: 48

Acute T Cell Leukemia

Categories: Rare diseases, Blood diseases, Skin diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Acute T Cell Leukemia

MalaCards integrated aliases for Acute T Cell Leukemia:

Name: Acute T Cell Leukemia 12 14
T-Cell Acute Lymphoblastic Leukemia 12 28
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 69
Precursor T-Cell Lymphoblastic Lymphoma 69
Precursor T Lymphoblastic Leukemia 12
Leukemia, Acute T-Cell 13

Classifications:



External Ids:

Disease Ontology 12 DOID:5603
ICD10 32 C91.5 C91.50
MeSH 41 D015459
NCIt 46 C3184

Summaries for Acute T Cell Leukemia

MalaCards based summary : Acute T Cell Leukemia, also known as t-cell acute lymphoblastic leukemia, is related to precursor t-cell acute lymphoblastic leukemia and t-cell leukemia. An important gene associated with Acute T Cell Leukemia is BCL10 (B Cell CLL/Lymphoma 10), and among its related pathways/superpathways are p53 Signaling and Tuberculosis. The drugs Arranon and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include t cells, thyroid and b cells, and related phenotypes are cellular and hematopoietic system

Related Diseases for Acute T Cell Leukemia

Graphical network of the top 20 diseases related to Acute T Cell Leukemia:



Diseases related to Acute T Cell Leukemia

Symptoms & Phenotypes for Acute T Cell Leukemia

MGI Mouse Phenotypes related to Acute T Cell Leukemia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.06 CASP8 LMO2 LPP CD151 ZFP36L2 CXCL12
2 hematopoietic system MP:0005397 9.97 CASP8 LMO2 CD151 ZFP36L2 CD7 CXCL12
3 endocrine/exocrine gland MP:0005379 9.91 CASP8 ZFP36L2 CD7 BAX FASLG HSD17B1
4 immune system MP:0005387 9.91 CASP8 LMO2 CD151 ZFP36L2 CD7 CXCL12
5 mortality/aging MP:0010768 9.85 CASP8 LMO2 LPP CD151 ZFP36L2 CXCL12
6 neoplasm MP:0002006 9.43 CASP8 LMO2 CD151 ZFP36L2 BAX FASLG
7 renal/urinary system MP:0005367 9.1 CASP8 LMO2 CD151 ZFP36L2 BAX FASLG

Drugs & Therapeutics for Acute T Cell Leukemia

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Arranon 17 45 NELARABINE GlaxoSmithKline October 2005

Drugs for Acute T Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupivacaine Approved, Investigational Phase 4,Phase 1,Phase 2 38396-39-3, 2180-92-9 2474
2
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
3 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
4 Central Nervous System Depressants Phase 4,Phase 1,Phase 2
5 Anesthetics Phase 4,Phase 1,Phase 2
6 Anesthetics, Local Phase 4,Phase 1,Phase 2
7 Calamus Nutraceutical Phase 4
8
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
9
Asparaginase Approved, Investigational Phase 3,Phase 2,Phase 1 9015-68-3
10
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
11
Daunorubicin Approved Phase 3,Phase 2 20830-81-3 30323
12
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
13
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
14
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
15
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
16
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
17
Dasatinib Approved, Investigational Phase 2, Phase 3, Phase 1 302962-49-8 3062316
18
Fludarabine Approved Phase 3,Phase 1 21679-14-1, 75607-67-9 30751
19
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
20
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 657311 5754
21
Ifosfamide Approved Phase 3 3778-73-2 3690
22
Bortezomib Approved, Investigational Phase 2, Phase 3 179324-69-7 387447 93860
23
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
24
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1 3375-50-6 598
25
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
26
Thioguanine Approved Phase 3,Phase 2 154-42-7 2723601
27
Pegaspargase Approved, Investigational Phase 3,Phase 2,Phase 1 130167-69-0
28
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
29
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
30
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
31
Idarubicin Approved Phase 3,Phase 2 58957-92-9 42890
32
Amsacrine Approved, Investigational Phase 2, Phase 3 51264-14-3 2179
33
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
34
Cortisone acetate Approved, Investigational Phase 3,Phase 2 1950-04-4, 50-04-4 5745
35
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
36
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
37
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
38
Blinatumomab Approved, Investigational Phase 2, Phase 3 853426-35-4
39
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
41
Butyric Acid Experimental, Investigational Phase 3,Phase 2 107-92-6 264
42
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
43 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
44 BB 1101 Phase 3,Phase 2,Phase 1
45 razoxane Phase 3
46 Isophosphamide mustard Phase 3 0
47 interferons Phase 3
48 Alkylating Agents Phase 3,Phase 2,Phase 1
49 glucocorticoids Phase 3,Phase 2,Phase 1
50
protease inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 96)

# Name Status NCT ID Phase Drugs
1 Neurotoxicity of Spinal Anesthesia With Ropivacaine and Bupivacaine Recruiting NCT03293472 Phase 4 Ropivacaine;Bupivacaine
2 Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
3 Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
4 Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III Completed NCT00483132 Phase 3 interferon alpha 2a
5 ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy Completed NCT00816049 Phase 3 6MPindividualized;6MPfixed
6 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia Completed NCT00613457 Phase 3 dexamethasone;asparaginase;Asparaginase;cyclophosphamide;cytarabine;daunorubicin;doxorubicin;Etoposide;Ifosfamide;mercaptopurine;Methotrexate;prednisone;thioguanine;Vincristine;Vindesine
7 Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment Recruiting NCT02881086 Phase 3 Rituximab;Nelarabine;PEG-Asparaginase;Imatinib;Idarubicin;Dexamethasone;Cyclophosphamide;Fludarabine;Vincristine;Mercaptopurine;VP16;Daunorubicin (DNR);Methotrexate;Cytarabine;Vindesine;Adriamycin;Prednisolone
8 Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL Recruiting NCT01228331 Phase 2, Phase 3 Amsacrine;Clofarabine;Cyclophosphamide;Cytarabine;Daunorubicin hydrochloride;Dexamethasone;Doxorubicin hydrochloride;Etoposide phosphate;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Thioguanine;Vincristine sulfate
9 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting NCT03117751 Phase 2, Phase 3 Prednisone;Vincristine;Daunorubicin;Pegaspargase;Erwinase®;Rituximab;Cyclophosphamide;Cytarabine;Mercaptopurine;Dasatinib;Methotrexate;Blinatumomab;Ruxolitinib;Bortezomib;Dexamethasone;Doxorubicin;Etoposide;Clofarabine;Vorinostat;Idarubicin
10 A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Recruiting NCT02716233 Phase 3 pegaspargase 1250 IU/m2 x 2;pegaspargase 2500 IU/m2 x 1
11 Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Recruiting NCT03007147 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Dexrazoxane Hydrochloride;Doxorubicin;Etoposide;Ifosfamide;Imatinib Mesylate;Leucovorin Calcium;Mercaptopurine;Mercaptopurine;Mesna;Methotrexate;Methylprednisolone;Pegaspargase;Prednisolone;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
12 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Recruiting NCT03020030 Phase 3 Pegaspargase;Erwinia asparaginase;Cyclophosphamide;CYTARABINE;DASATINIB;DEXAMETHASONE;Dexrazoxane;Doxorubicin;ETOPOSIDE;HYDROCORTISONE;LEUCOVORIN CALCIUM;MERCAPTOPURINE;METHOTREXATE;NELARABINE;Vincristine
13 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Active, not recruiting NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
14 International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia Active, not recruiting NCT01117441 Phase 3 PEG-L-asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine;daunoxome;fludarabine
15 Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Suspended NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
16 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL) Completed NCT00684619 Phase 2 Nelarabine
17 Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia or T-Lymphoblastic Lymphoma With MabCampath Completed NCT00199030 Phase 2 Alemtuzumab (MabCampath);Cladribine
18 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma Completed NCT00061048 Phase 2
19 Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) Completed NCT00687323 Phase 2 temozolomide
20 Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia Completed NCT00095381 Phase 2 forodesine hydrochloride (BCX-1777)
21 Losartan Versus Atenolol for the Treatment of Marfan Syndrome Completed NCT00593710 Phase 2 Losartan;Atenolol
22 506U78 in Treating Patients With Refractory Hematologic Cancer Completed NCT00002970 Phase 2 nelarabine;methotrexate;cytarabine;therapeutic hydrocortisone
23 Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
24 Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed NCT00873093 Phase 2 L-asparaginase;doxorubicin hydrochloride;therapeutic hydrocortisone;vincristine sulfate;cytarabine;prednisone;bortezomib;pegaspargase;methotrexate;etoposide phosphate;cyclophosphamide;leucovorin calcium;High Dose MTX
25 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
26 BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Recruiting NCT02763384 Phase 2 BL-8040;Nelarabine
27 Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Recruiting NCT02518750 Phase 2 Dexamethasone;Panobinostat;Liposomal vincristine;Mitoxantrone;Peg-asparaginase;Bortezomib;Intrathecal Triples;High-dose methotrexate;6-Mercaptopurine;High-dose cytarabine;Nelarabine;Cyclophosphamide;Etoposide;Clofarabine
28 Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma Recruiting NCT00501826 Phase 2 Doxorubicin;Cyclophosphamide;Cytarabine;Dexamethasone;Methotrexate;Vincristine;Nelarabine;Mesna;6-MP;Prednisone
29 Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia Recruiting NCT02767934 Phase 2
30 Dose-finding Study of Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia Recruiting NCT02654860 Phase 1, Phase 2 Paracetamol 3%;Placebo injection containing Saline solution 0.9%;Hyperbaric Bupivacaine HCl 0.5%
31 Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia Recruiting NCT02484430 Phase 2 Sapanisertib
32 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Recruiting NCT02742727 Phase 1, Phase 2
33 A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL Active, not recruiting NCT02518113 Phase 1, Phase 2 LY3039478;Dexamethasone;Placebo
34 Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma Active, not recruiting NCT00866749 Phase 2 Daunorubicin;Vincristine;PEG-asparaginase;Intrathecal Methotrexate;Cyclophosphamide;Cytarabine;Mercaptopurine;Methotrexate;Doxorubicin;Thioguanine
35 Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia Active, not recruiting NCT00792948 Phase 2 Cyclophosphamide;Cytarabine;Dasatinib;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Leucovorin Calcium;Methotrexate;Methylprednisolone;Prednisone;Sirolimus;Tacrolimus;Vincristine Sulfate
36 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Active, not recruiting NCT01811212 Phase 2 Cabozantinib S-malate
37 A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leuk Not yet recruiting NCT03384654 Phase 2 Daratumumab;Vincristine;Prednisone;Doxorubicin;Cyclophosphamide;Cytarabine;6-mercaptopurine;Methotrexate
38 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) Not yet recruiting NCT03207542 Phase 2 Daratumumab
39 Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Not yet recruiting NCT02538926 Phase 2 Asparaginase;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Imatinib Mesylate;Prednisone;Vincristine Sulfate
40 Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery Not yet recruiting NCT02973997 Phase 2 Lenvatinib
41 TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients Terminated NCT00415909 Phase 2 Imatinib Mesylate (IM);TALL-104 cells
42 Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL Terminated NCT00981799 Phase 1, Phase 2 Nelarabine;Etoposide;Cyclophosphamide;Methotrexate;Filgrastim
43 Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia Terminated NCT02999633 Phase 2 Isatuximab SAR650984;dexamethasone;dexamethasone;acetaminophen;ranitidine;diphenhydramine
44 Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens Terminated NCT00419081 Phase 2 Forodesine Hydrochloride Sterile Solution, 5 mg/mL;Forodesine Hydrochloride Capsules (100 mg)
45 A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Terminated NCT01483690 Phase 1, Phase 2 Decitabine;Vorinostat;Vincristine;Dexamethasone;Mitoxantrone;Pegaspargase;Methotrexate
46 Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma. Terminated NCT00742495 Phase 1, Phase 2 Forodesine
47 Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Terminated NCT01005914 Phase 2 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;imatinib mesylate;methotrexate;methylprednisolone;pegaspargase;vincristine sulfate
48 Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma Completed NCT00406757 Phase 1 Nelarabine injection 400mg/m2;Nelarabine injection 650mg/m2;Nelarabine injection 1000mg/m2;Nelarabine injection 1500mg/m2
49 A Trial In Patients With Advanced Cancer And Leukemia Completed NCT00878189 Phase 1 PF-03084014
50 Distraction Osteogenesis in Limb-length Discrepancy With Mesenchymal Cell Transplantation Completed NCT01210950 Phase 1

Search NIH Clinical Center for Acute T Cell Leukemia

Genetic Tests for Acute T Cell Leukemia

Genetic tests related to Acute T Cell Leukemia:

# Genetic test Affiliating Genes
1 T-Cell Acute Lymphoblastic Leukemia 28

Anatomical Context for Acute T Cell Leukemia

MalaCards organs/tissues related to Acute T Cell Leukemia:

38
T Cells, Thyroid, B Cells, Bone, Brain, Myeloid, Bone Marrow

Publications for Acute T Cell Leukemia

Articles related to Acute T Cell Leukemia:

(show all 29)
# Title Authors Year
1
Hepatic leukemia-associated macrophages exhibit a pro-inflammatory phenotype in Notch1-induced acute T cell leukemia. ( 29030004 )
2018
2
Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement. ( 27756877 )
2016
3
Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia inA vivo in a mouse xenogtraft model. ( 27998762 )
2016
4
Articulatin-D induces apoptosis via activation of caspase-8 in acute T-cell leukemia cell line. ( 27868169 )
2016
5
CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance. ( 26058075 )
2015
6
Inhibition of hedgehog signaling by GANT58 induces apoptosis and shows synergistic antitumor activity with AKT inhibitor in acute T cell leukemia cells. ( 24394624 )
2014
7
Mir-55 inhibition can reduce cell proliferation and induce apoptosis in Jurkat (Acute T cell Leukemia) cell line. ( 25598954 )
2014
8
Effects of hydroxylated resveratrol analogs on oxidative stress and cancer cells death in human acute T cell leukemia cell line: Prooxidative potential of hydroxylated resveratrol analogs. ( 24398169 )
2014
9
Conversion of estrone to 17 beta-estradiol in Jurkat acute T cell leukemia Hut-78 T- and Raji B lymphoma cell lines in vitro. ( 23540283 )
2013
10
Combined treatment with fenretinide and indomethacin induces AIF-mediated, non-classical cell death in human acute T-cell leukemia Jurkat cells. ( 22387538 )
2012
11
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. ( 20008304 )
2010
12
Complete regression of massive cardiac involvement associated with acute T cell leukemia following chemotheraphy. ( 17320483 )
2008
13
Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias. ( 16502262 )
2006
14
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. ( 16332967 )
2006
15
Post-transplantation lymphoproliferative disorder of recipient origin in a boy with acute T-cell leukemia with detection of B-cell clonality 3 months before stem cell transplantation. ( 16266918 )
2005
16
HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). ( 15774621 )
2005
17
Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. ( 14715100 )
2003
18
A novel post-transcriptional splicing form of the acute T cell leukemia proto-oncogene Lmo2. ( 18763096 )
2001
19
Identification of a member of the TIS11 early response gene family at the insertion point of a DNA fragment containing a gene for the T-cell receptor beta chain in an acute T-cell leukemia. ( 8545129 )
1995
20
Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. ( 1371092 )
1992
21
Acute T-cell leukemia/lymphoma mimicking Hodgkin's disease with secondary HTLV I seroconversion. ( 2208004 )
1990
22
Constitutive expression and abnormal glycosylation of transferrin receptor in acute T-cell leukemia. ( 2582441 )
1989
23
A case of CD3+, CD4-, CD8-, WT31- acute T-cell leukemia. ( 2787596 )
1989
24
Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemia. ( 2546621 )
1989
25
Cyclosporine A and acute T cell leukemia in the rat. ( 3164536 )
1988
26
T-lymphoblasts with erythropoietic helper function in acute T-cell leukemia. ( 2978965 )
1986
27
Childhood primary cutaneous non-T/non-B lymphoma followed by acute T-cell leukemia. ( 3486034 )
1986
28
t(11;19)(q23;p11) in a child with acute T-cell leukemia. ( 3855377 )
1985
29
Human serum thymic factor in detecting acute T cell leukemia. ( 311636 )
1978

Variations for Acute T Cell Leukemia

ClinVar genetic disease variations for Acute T Cell Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 BAX NM_138761.3(BAX): c.199G> A (p.Gly67Arg) single nucleotide variant Pathogenic rs398122513 GRCh37 Chromosome 19, 49459056: 49459056
2 BAX NM_138761.3(BAX): c.115_121delGGGGGGG (p.Gly39Argfs) deletion Pathogenic rs398122842 GRCh37 Chromosome 19, 49458972: 49458978
3 BCL10 NM_003921.4(BCL10): c.136_137insA (p.Ile46Asnfs) insertion Pathogenic rs387906351 GRCh37 Chromosome 1, 85736511: 85736511

Copy number variations for Acute T Cell Leukemia from CNVD:

7 (show top 50) (show all 91)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21835 1 16200000 23900000 Copy number CHD5 T-cell acute lymphoblastic leukemia
2 21836 1 16200000 23900000 Copy number HES2 T-cell acute lymphoblastic leukemia
3 21837 1 16200000 23900000 Copy number HES3 T-cell acute lymphoblastic leukemia
4 32217 1 34600000 44100000 Copy number T-cell acute lymphoblastic leukemia
5 34248 1 5400000 7200000 Deletion T-cell acute lymphoblastic leukemia
6 38166 10 1 3800000 Copy number T-cell acute lymphoblastic leukemia
7 41844 10 24600000 31300000 Copy number ADARB2 T-cell acute lymphoblastic leukemia
8 41845 10 24600000 31300000 Copy number PFKP T-cell acute lymphoblastic leukemia
9 41846 10 24600000 31300000 Copy number PITRM1 T-cell acute lymphoblastic leukemia
10 41847 10 24600000 31300000 Copy number WDR37 T-cell acute lymphoblastic leukemia
11 46873 10 87900000 92900000 Loss PTEN T-cell acute lymphoblastic leukemia
12 48336 11 1 2800000 Gain IGF2 T-cell acute lymphoblastic leukemia
13 48337 11 1 2800000 Gain hsa-mir-675 T-cell acute lymphoblastic leukemia
14 48490 11 1 52900000 Duplication T-cell acute lymphoblastic leukemia
15 53563 11 31000000 36400000 Copy number WT1 T-cell acute lymphoblastic leukemia
16 57103 11 63100000 67100000 Gain MAP4K2 T-cell acute lymphoblastic leukemia
17 57104 11 63100000 67100000 Gain RASGRP2 T-cell acute lymphoblastic leukemia
18 60336 11 85300000 87900000 Loss PICALM T-cell acute lymphoblastic leukemia
19 60878 11 92800000 110400000 Copy number ATM T-cell acute lymphoblastic leukemia
20 61471 12 1 14800000 Deletion T-cell acute lymphoblastic leukemia
21 61531 12 1 35400000 Duplication T-cell acute lymphoblastic leukemia
22 61611 12 10000000 12600000 Loss CDKN1B T-cell acute lymphoblastic leukemia
23 61613 12 10000000 12600000 Loss hsa-mir-614 T-cell acute lymphoblastic leukemia
24 61779 12 10100000 14800000 Copy number CDKN1B T-cell acute lymphoblastic leukemia
25 74382 13 105800000 109100000 Gain TNFSF13B T-cell acute lymphoblastic leukemia
26 78375 13 50900000 55300000 Deletion DLEU7 T-cell acute lymphoblastic leukemia
27 78376 13 50900000 55300000 Deletion KCNRG T-cell acute lymphoblastic leukemia
28 82826 14 15600000 23600000 Deletion T-cell acute lymphoblastic leukemia
29 88309 6 135544145 135582003 Copy number MYB T-cell acute lymphoblastic leukemia
30 104069 16 66700000 70800000 Deletion CTCF T-cell acute lymphoblastic leukemia
31 108732 17 22200000 28800000 Duplication T-cell acute lymphoblastic leukemia
32 109390 17 25800000 31800000 Copy number NF1 T-cell acute lymphoblastic leukemia
33 109749 17 28800000 35400000 Deletion T-cell acute lymphoblastic leukemia
34 111430 17 3600000 6800000 Loss NALP1 T-cell acute lymphoblastic leukemia
35 115247 17 55600000 58400000 Gain MSI2 T-cell acute lymphoblastic leukemia
36 115248 17 55600000 58400000 Gain VEZF1 T-cell acute lymphoblastic leukemia
37 115617 17 58400000 59900000 Gain MAP3K3 T-cell acute lymphoblastic leukemia
38 115618 17 58400000 59900000 Gain SMURF2 T-cell acute lymphoblastic leukemia
39 115619 17 58400000 59900000 Gain hsa-mir-633 T-cell acute lymphoblastic leukemia
40 115878 17 59900000 64600000 Gain PRKCA T-cell acute lymphoblastic leukemia
41 116600 17 68400000 72200000 Gain GPR142 T-cell acute lymphoblastic leukemia
42 116601 17 68400000 72200000 Gain GPRC5C T-cell acute lymphoblastic leukemia
43 121278 18 41800000 46400000 Loss SMAD4 T-cell acute lymphoblastic leukemia
44 124174 19 1 6900000 Gain MKNK2 T-cell acute lymphoblastic leukemia
45 131214 19 53800000 57600000 Gain FUT2 T-cell acute lymphoblastic leukemia
46 131215 19 53800000 57600000 Gain RASIP1 T-cell acute lymphoblastic leukemia
47 133723 19 6900000 12600000 Gain INSR T-cell acute lymphoblastic leukemia
48 133733 19 6900000 13900000 Deletion T-cell acute lymphoblastic leukemia
49 140125 2 19200000 27900000 Copy number NCOA1 T-cell acute lymphoblastic leukemia
50 140126 2 19200000 27900000 Copy number TP53I3 T-cell acute lymphoblastic leukemia

Expression for Acute T Cell Leukemia

Search GEO for disease gene expression data for Acute T Cell Leukemia.

Pathways for Acute T Cell Leukemia

GO Terms for Acute T Cell Leukemia

Biological processes related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.63 BCL10 CASP8 FASLG
2 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.58 BAX CASP8 FASLG
3 apoptotic signaling pathway GO:0097190 9.54 BAX CASP8 FASLG
4 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.49 CASP8 FASLG
5 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.48 BAX FASLG
6 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.43 CASP8 FASLG
7 extrinsic apoptotic signaling pathway GO:0097191 9.33 BAX CASP8 FASLG
8 B cell apoptotic process GO:0001783 9.32 BAX BCL10
9 T cell apoptotic process GO:0070231 9.26 BCL10 FASLG
10 retinal cell programmed cell death GO:0046666 8.96 BAX FASLG
11 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 8.8 BAX CASP8 FASLG

Molecular functions related to Acute T Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 8.96 CASP8 FASLG
2 death receptor binding GO:0005123 8.62 CASP8 FASLG

Sources for Acute T Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....